Comparative Pharmacology
Head-to-head clinical analysis: ACETIC ACID W HYDROCORTISONE versus ARISTOCORT A.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACETIC ACID W HYDROCORTISONE versus ARISTOCORT A.
ACETIC ACID W/ HYDROCORTISONE vs ARISTOCORT A
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Acetic acid exerts antibacterial and antifungal activity by lowering pH and disrupting microbial cell membranes. Hydrocortisone is a corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties.
Triamcinolone acetonide is a corticosteroid that binds to glucocorticoid receptors, modulating gene expression to inhibit phospholipase A2, reduce prostaglandin and leukotriene synthesis, suppress cytokine production, and decrease inflammation and immune responses.
1 applicatorful (approximately 5 g) of the cream or ointment (containing 2% acetic acid and 1% hydrocortisone) inserted intravaginally once or twice daily for 7 days.
Intralesional injection: 2.5-5 mg per lesion, repeated every 1-2 weeks. Topical: Apply thin film to affected area 2-4 times daily.
None Documented
None Documented
Acetic acid: not applicable; hydrocortisone: plasma half-life ~1.5 hours (biologic half-life 8–12 hours). Due to low systemic absorption from topical application, systemic half-life is clinically irrelevant.
Terminal half-life: 2-3 hours for triamcinolone acetonide. Clinical context: Duration of action longer due to receptor binding and intracellular activity; anti-inflammatory effects persist 24-48 hours after IM administration.
Acetic acid: minimal systemic absorption; hydrocortisone: hepatic metabolism, renal excretion of metabolites (<5% unchanged). Less than 10% of applied dose excreted in urine as metabolites; biliary/fecal excretion negligible.
Renal: 75% as metabolites (primarily conjugated), 15% as unchanged drug. Biliary/fecal: 10%.
Category D/X
Category C
Corticosteroid
Corticosteroid